CHGCY:OTC-Chugai Pharmaceutical Co., Ltd (USD)

COMMON STOCK | Drug Manufacturers-General | OTC

Last Closing Price

USD 23.80

Change

+0.03 (+0.11)%

Market Cap

USD 80.63B

Volume

0.02M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, marketing, and distribution of prescription medicines in Japan and internationally. The company's products for oncology primarily include Avastin, Herceptin, Rituxan, Alecensa, Perjeta, Xeloda, Tarceva, Kadcyla, Zelboraf, Neutrogin, Tecentriq, and Gazyva; bone and joint diseases/autoimmune diseases comprise Actemra, Edirol, Suvenyl, and Bonviva; renal diseases consist of Mircera and Oxarol; and other diseases comprise Tamiflu, CellCept, Copegus, and Hemlibra. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group and Genentech; and co-development agreements with Taisho Pharmaceutical Co., Ltd. and Nippon Shinyaku Co., Ltd. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-12-04 )

Largest Industry Peers for Drug Manufacturers-General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
RHHVF Roche Holding AG

+0.74 (+0.22%)

USD288.90B 27.38 14.53
RHHBY Roche Holding AG

+0.92 (+2.20%)

USD285.03B 21.54 14.53
RHHBF Roche Holding AG

-2.00 (-0.58%)

USD284.92B 27.85 13.75
NVSEF Novartis AG

-0.93 (-1.02%)

USD207.09B 29.63 13.82
AZNCF AstraZeneca PLC

+0.29 (+0.27%)

USD135.60B 55.66 18.10
SNYNF Sanofi

-1.46 (-1.43%)

USD130.51B 26.35 7.63
GLAXF GlaxoSmithKline plc

+0.56 (+3.07%)

USD92.20B 36.77 14.31
CHGCF Chugai Pharmaceutical Co., Ltd

N/A

USD77.88B 41.79 0.26
DSNKY Daiichi Sankyo Company, Limite..

-0.59 (-1.74%)

USD65.85B 34.92 0.36
DSKYF Daiichi Sankyo Company, Limite..

N/A

USD65.77B 35.78 0.36

ETFs Containing CHGCY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 53.90% 94% A 76% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 53.90% 94% A 75% C
Trailing 12 Months  
Capital Gain 57.36% 94% A 76% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 57.36% 94% A 75% C
Trailing 5 Years  
Capital Gain 304.53% 93% A 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 304.53% 93% A 86% B
Average Annual (5 Year Horizon)  
Capital Gain 38.51% N/A N/A 78% C+
Dividend Return 0.20% N/A N/A 10% F
Total Return 38.71% N/A N/A 77% C+
Risk Return Profile  
Volatility (Standard Deviation) 33.28% N/A N/A 53% F
Risk Adjusted Return 116.30% N/A N/A 98% A+
Market Capitalization 80.63B 79% C+ 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 8.56 94% A 69% D+
Price/Book Ratio 8.16 21% F 17% F
Price / Cash Flow Ratio 0.39 62% D- 43% F
EV/EBITDA 0.26 71% C- 74% C
Management Effectiveness  
Return on Equity 23.31% 74% C 92% A-
Return on Invested Capital 19.91% 82% B- 83% B
Return on Assets 16.02% 91% A- 98% A+
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.80 29% F 54% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector